| Literature DB >> 35101404 |
Ayman A Hussein1, Paulino Alvarez2, Grant Reed3, Gustavo A Heresi4.
Abstract
Direct oral anticoagulants (DOACs) are increasingly used in clinical practice and have become essential in the management of atrial fibrillation and VTE. The enthusiasm for DOACs has fueled the off-label application of these agents in cardiopulmonary disease, and their use has often outpaced the evidence supporting their application. This article reviews the evidence and current off-label use of DOACs in various cardiopulmonary disease states.Entities:
Keywords: direct oral anticoagulant; off-label use; thromboembolism
Mesh：
Substances：
Year: 2022 PMID： 35101404 DOI： 10.1016/j.chest.2022.01.033
Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410